WO1993017037A1 - Treatment of acute migraine or cluster headache attacks - Google Patents
Treatment of acute migraine or cluster headache attacks Download PDFInfo
- Publication number
- WO1993017037A1 WO1993017037A1 PCT/EP1993/000366 EP9300366W WO9317037A1 WO 1993017037 A1 WO1993017037 A1 WO 1993017037A1 EP 9300366 W EP9300366 W EP 9300366W WO 9317037 A1 WO9317037 A1 WO 9317037A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- migraine
- residue
- residues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
Definitions
- the present invention relates to a new use, in particular a new use for the compound group comprising somatostatin analogues and derivatives, in free form or in pharmaceutically acceptable salt or complex form, said compound group being referred to herein-after collectively as COMPOUNDS OF THE INVENTION.
- somatostatin analogue or derivative any straight-chain or cyclic polypeptide derived from that of the naturally occurring tetradecapeptide somatostatin wherein one or more amino acid units have been omitted and/or replaced by one or more other amino acid radical(s) and/or wherein one or more functional groups have been replaced by one or more other functional groups and/or one or more groups have been replaced by one or several other isosteric groups.
- the term covers all modified derivatives of the naturally occurring somatostatin peptide which exhibit a qualitatively similar effect to that of the unmodified somatostatin peptide, e.g. they bind to somatostatin receptors and decrease hormone secretion.
- A is C 1-12 alkyl, C 7-10 phenylalkyl or a group of formula RCO-, whereby
- R is hydrogen, C 1-11 alkyl, phenyl or C 7-10 phenylalkyl, or ii) RCO- is a) an L- or D-phenylalanine residue optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy; b) the residue of a natural or a non natural ⁇ -amino-acid other than defined under a) above, or of a corresponding D-amino acid, or c) a dipeptide residue in which the individual amino acid
- residues are the same or different and are selected from those defined under a) and/or b) above, the ⁇ -amino group of amino acid residues a) or b) and the N-terminal amino group of dipeptide residues c) being optionally mono- or di-C 1-12 alkylated or substituted by C 1-8 alkanoyl or benzyl;
- A' is hydrogen or C 1-3 alkyl
- Y 1 and Y 2 represent together a direct bond
- each of Y 1 and Y 2 is independently hydrogen or a radical of
- R a is methyl or ethyl
- R b is hydrogen, methyl or ethyl
- m is a whole number from 1 to 4
- n is a whole number from 1 to 5
- R c is (C 1-6 )alkyl
- R d represents the substituent attached to the ⁇ -carbon atom of a natural or non natural ⁇ -amino acid (including hydrogen)
- R e is (C 1-5 )alkyl
- R a ' and R b ' are independently hydrogen, methyl or ethyl
- R 8 and R 9 are independently hydrogen, halogen, (C 1-3 )alkyl or
- p 0 or 1
- q 0 or 1
- r 0, 1 or 2
- B is -Phe- optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and /or C 1-3 alkoxy (including pentafluoro- alanine), or naphthylalanine C is (L)-Trp- or (D)-Trp- optionally ⁇ -N-methylated and optionally benzene-ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy,
- D is Lys, Lys in which the side chain contains O or S in
- E is Thr, Ser, Val, Phe, Tyr, Ile or an aminobutyric or aminoisobutyric acid residue
- G is a group of formula
- R 7 is hydrogen or C 1-3 alkyl
- R 10 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester
- R 11 is hydrogen, C 1-3 alkyl, phenyl or C 7-10 phenyl-alkyl,
- R 12 is hydrogen, C 1-3 alkyl or a group of formula -CH(R 13 )-X 1 , R 13 is CH 2 OH, -(CH 2 ) 2 -OH, -(CH 2 ) 3 -OH, or -CH(CH 3 )OH or represents the substituent attached to the ⁇ -carbon atom of a natural or non natural ⁇ -amino acid (including hydrogen) and
- X 1 is a group of formula -COOR 7 , -CH 2 OR 10 or wherein
- R 7 and R 10 have the meanings given above,
- R 14 is hydrogen or C 1-3 alkyl
- R 15 is hydrogen, C 1-3 alkyl, phenyl or C 7-10 phenylalkyl, and
- R 16 is hydrogen or hydroxy, with the proviso that
- R 12 when R 12 is -CH(R 13 )-X 1 then R 11 is hydrogen or methyl, wherein the residues B, D and E have the L-configuration, and the residues in the 2- and 7-position and any residues Y 1 4) and Y 2 4) each independently have the (L)- or (D)- configuration, in free form or in pharmaceutically acceptable salt or complex form.
- Phenylalkyl as A or R is preferably phenethyl.
- R has the meaning a) this is preferably a') an L- or D-phenylalanine or -tyrosine residue. More preferably a') is an L- or D-phenylalanine residue.
- residues b) are ⁇ -amino acid residues having a hydrocarbon side chain, e.g. alkyl with 3, preferably 4, or more C atoms, e.g. up to 7 C-atoms, or a naphthyl-methyl or heteroaryl side chain, e.g. pyridyl-methyl or indol-3-yl-methyl, said residues having the L- or D-configuration.
- Preferred residues c) are dipeptide residues in which the individual amino acid residues are the same or different and are selected from those defined under a') and b') above.
- N-terminal amino group of dipeptide residues c) is preferably non-alkylated or mono-C 1-12 alkylated, especially -C 1-8 alkylated, more especially -methylated. Most preferably the N-terminal is non-alkylated.
- R has the meaning a) especially the meaning a').
- B is B', where B' is Phe or Tyr.
- C is C, where C is (D)Trp.
- D is D', where D' is Lys, MeLys, especially Lys.
- E is E', where E' is Ser, Val or Thr, especially Thr.
- G is G', where G' is a group of formula
- R 11 is preferably hydrogen.
- R 13 is preferably -CH 2 OH,
- X 1 is preferably a group of formula
- R 10 is preferably hydrogen or, as an ester residue, formyl, C 2-12 alky1carbony1, C 8-12 phenylalkylcarbonyl or benzoyl. Most preferably R 10 is hydrogen.
- the COMPOUNDS OF THE INVENTION may exist e.g. in free form, salt form or in the form of complexes thereof.
- Acid addition salts may be formed with e.g. organic acids, polymeric acids and inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides and acetates.
- Complexes are e.g. formed from compounds of the invention on addition of inorganic substances, e.g.
- inorganic salts or hydroxides such as Ca- and Zn-salts, and/or an addition of polymeric organic substances.
- COMPOUNDS OF THE INVENTION have, on the basis of observed activity, e.g. inhibition of GH secretion in rats and/or inhibition of pancreatic and gastric secretion in rats, e.g. as described in EP-B-29579, been found to be useful e.g. in the treatment of acromegaly, complications of diabetes mellitus or gastro-intestinal disorders.
- Migraine is a familial disorder characterized by periodic commonly unilateral, throbbing headaches which begin in
- Migraine episodes usually have one or more of the following characteristics; episodic nature lasting 4-72 hours, unilateral location, accompanying nausea, pulsating characteristic of pain, photophobia and phonophobia, autonomic disturbances and tenderness of the scalp on the side of the headache.
- One main aspect of the treatment consists in pharmacologically aborting acute attacks.
- Cluster headache is a craniofacial pain syndrome which can be distinguished clinically from migraine. Attacks of headache occur in clusters during a period of weeks or months followed by often prolonged painfree periods. Between 1 and 4 attacks of 10-240 min duration may occur in a single day. There also exists a need for adequate treatment of cluster headache attacks.
- COMPOUNDS OF THE INVENTION when administered nasally, have a fast onset of action in the treatment of acute attacks of migraine or cluster headache in subjects who do not suffer from pituitary tumors.
- a method for treating acute attacks of migraine or cluster headache in a subject in need of such therapy comprising administering nasally to said subject a therapeutically effective amount of a COMPOUND OF THE INVENTION.
- the present invention also provides:
- a COMPOUND OF THE INVENTION for use in the manufacture of a nasal pharmaceutical composition for use in the treatment of acute attacks of migraine or cluster headache.
- a nasal pharmaceutical composition for use in the treatment of acute attacks of migraine or cluster headache comprising a COMPOUND OF THE INVENTION together with one or more diluents or carriers adapted for nasal administration.
- the COMPOUNDS OF THE INVENTION are administered in the form of a composition adapted for nasal administration. They may be administered in the form of liquid or solid, e.g. in nasal spray, drop, gel or powder form, or nasal inserts.
- Liquid nasal compositions may comprise a COMPOUND OF THE
- compositions may contain further ingredients or excipients, e.g.
- a substance for adjusting the pH preferably tp a mildly acid pH, e.g. of from about 4 to 5, preferably about 4.2, for example a mineral or organic acid, e.g. HCl,
- a substance for adjusting isotonicity e.g. glucose, ribose, mannose, arabinose, xylose, glucosamine or NaCl,
- a stabilizing and/or preserving agent e.g. thiomersal
- Such a preserving agent may be present in an amount of from ca. 0.05 to 0.2 mg/ml.
- Suitable nasal inserts include e.g. a device which is sized, shaped or adapted for placement and retention into the naris e.g. nasal plugs, tampons and the like, breathing being not significantly inhibited.
- the COMPOUND OF THE INVENTION may be carried on the insert, e.g. by adsorption onto the surface thereof or in the form of a coating, and/or in the insert, e.g. by absorption or by any other convenient means.
- the COMPOUND OF THE INVENTION may be carried in combination with one or more nasally acceptable diluents or carriers.
- the material from which the insert is made may be for example a porous material, e.g.
- a polymer capable of forming a porous matrix e.g. gelatin, acrylate polymers, hydroxypropyl cellulose, hydroxypropylmethyl cellulose (HPMC), or a fibrous material such as cotton wool or sponge material.
- HPMC hydroxypropylmethyl cellulose
- a fibrous material such as cotton wool or sponge material.
- COMPOUNDS OF THE INVENTION may be administered in the form of a powder.
- nasal powdered compositions suitable for the treatment according to the invention may be based on a carrier such as lactose or water-absorbing, water-insoluble,
- polyacrylates such as sodium polyacrylate, potassium polyacrylate and ammonium polyacrylates
- lower alkyl ethers of cellulose such as methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose
- polyvinyl pyrrolidone amylose and preferably polyethyleneglycol e.g.
- water-absorbing and water-insoluble starches such as hydroxypropyl starch, carboxymethyl starch, water-absorbing and water-insoluble proteins such as gelatin, casein; water-absorbing and water-insoluble gums such as gum arabic, tragacanth gum and glucomannan; and cross-linked vinyl polymers such as cross-linked polyvinyl pyrrolidone, cross-linked carboxyvinyl polymer or its salt, cross-linked polyvinyl alcohol and polyhydroxyethylmethylacrylate.
- water-absorbing and water-insoluble celluloses and cross-linked vinyl polymers are desirable, and water-absorbing and water-insoluble celluloses are more desirable and microcrystalline cellulose is especially desirable.
- the mean polymerisation number of the preferred polymers, microcrystalline cellulose is from about 200 to 2000, preferably 200 to 300.
- Preferred mean molecular weights are from about 20.000 to about 100.000 e.g. 30.000 to 50.000.
- These powders may be prepared by mixing a COMPOUND OF THE
- the particles may be coated.
- the COMPOUND may be in solution, e.g. an aqueous or alcoholic solution when being mixed with the particles and the solvent evaporated, e-g. under freeze-drying or spray drying. Such drying may be effected under conventional conditions.
- the mixture may be compacted or granulated and then be pulverized and/or sieved.
- the powder may be produced in the form of an insert e.g. as described above and then pulverized.
- the powder has a particle size of from 10 to
- the powdery pharmaceutical composition can be directly used as a powder for a unit dosage form. If desired the powder can be filled in capsules such as hard gelatine capsules. The contents of the capsule may be administered using e.g. an insufflator.
- the nasal powder may contain other excipients. Some excipients have been described above. For example sugars, such as lactose, stabilizing agents, isotonic agents may be present in the powder-form.
- the nasal powder to be used according to the invention may also contain an absorption promoter, in particular a non-ionic promoter, e.g. a non-ionic surfactant, suitable for application to the nasal mucosae.
- an absorption promoter in particular a non-ionic promoter, e.g. a non-ionic surfactant, suitable for application to the nasal mucosae.
- compositions adapted for nasal administration are disclosed e.g. in GB-A-2, 193,891, the contents of which being incorporated herein by reference.
- a particularly preferred nasal composition for use in the method of the invention is a powdery composition comprising a water-absorbing, water-insoluble diluent or carrier, e.g. microcrystalline cellulose.
- compositions comprising from 2.2 to 1.6 mg of a COMPOUND OF THE INVENTION, particularly octreotide, per 20 mg powder.
- Patients are included who have a mean monthly frequency of 2 to 6 attacks of migraine without aura/month during 3 months prior to entering the study period.
- the clinical trial excludes:
- cephalalgia e.g.
- Each patient receives three medication boxes containing each one capsule and an insufflator.
- Two capsules contain the compound to be tested, in powder form and at various concentrations; the third capsule is a placebo capsule. All three capsules are identical in their aspect.
- the migraine attack is treated within 3 hours following its onset. Migraine attacks are rated
- migraine attacks rated a 2 or 3 are treated.
- the patient administers to himself a total of 6 puffs, which permits to empty the capsule. Administration is made alternatively in each nostril (3/nostril).
- the patient uses the box corresponding to the particular attack (box labelled no. 1 for the first attack, no. 2 for the second migraine attack and no. 3 for the third attack). Two hours after administration, the patient is allowed to take another migraine medication, except for a nasal medication, if its symptoms have not improved.
- the physician records the migraine history of the patient, the results of neurologic and
- the patient rates the severity of the migraine attack
- This rating is done immediately before the nasal administrations, and then 30, 60, 120 minutes, 8 and 24 hours after the nasal administration.
- the patient records also: the total duration of the migraine attack; whether he needs a complementary medication; the existence of nausea and/or vomiting before and 2 hours after the treatment; rebound of migraine within the 24 hours after the treatment.
- daily dosages required in practicing the method of the present invention will, of course, vary depending on a variety of factors, for example the particular COMPOUND OF INVENTION chosen, the particular condition to be treated and the effect desired. In general however satisfactory results are indicated to be obtained at a dosage for nasal administration from about 3.5 ⁇ g/kg to about 300 ⁇ k/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range of from ca. 0.25 to 2 mg nasally. Suitable unit dosage forms for nasal administration thus comprise from ca. 0.25 to 2 mg active compound together with one or more pharmaceutically acceptable diluents or carriers therefor.
- composition for nasal administration in accordance with the invention.
- Example 1 is repeated but with addition of 3.0 mg/ml end composition powdered SOLULAN C24 (Polyoxyethylene-(24)-cholesteryl ether) together with components 1, 2 and 4 in the first production step.
- SOLULAN C24 Polyoxyethylene-(24)-cholesteryl ether
- a lyophilisate insert (plug) comprising the following: mg
- a nasal powder is prepared containing:
- Microcrystalline cellulose (Avicel PH 101- 18.61
- This powder is prepared in a charge for about 300 unit doses by mixing octreotide and about one quarter of the cellulose. The mixture is sieved. The remainder of the cellulose is then added and the mass is mixed thoroughly.
- the final powder has a particle diameter from about 20 to about 250 ⁇ . This powder is filled into capsules. Local and systemic tolerability is good for this nasal powder.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nasal administration of a somatostatin peptide analogue or derivative for treating acute attacks of migraine or cluster headache.
Description
TREATMENT OF ACUTE MIGRAINE OR CLUSTER HEADACHE ATTACKS
The present invention relates to a new use, in particular a new use for the compound group comprising somatostatin analogues and derivatives, in free form or in pharmaceutically acceptable salt or complex form, said compound group being referred to herein-after collectively as COMPOUNDS OF THE INVENTION.
By the terms "somatostatin analogue or derivative" as used herein is meant any straight-chain or cyclic polypeptide derived from that of the naturally occurring tetradecapeptide somatostatin wherein one or more amino acid units have been omitted and/or replaced by one or more other amino acid radical(s) and/or wherein one or more functional groups have been replaced by one or more other functional groups and/or one or more groups have been replaced by one or several other isosteric groups. In general, the term covers all modified derivatives of the naturally occurring somatostatin peptide which exhibit a qualitatively similar effect to that of the unmodified somatostatin peptide, e.g. they bind to somatostatin receptors and decrease hormone secretion.
Cyclic, bridge cyclic or straight-chain somatostatin analogues or derivatives are known. Such compounds and their preparation are described in European patent applications 29,579; 215,171;
203,031 and 214,872.
Preferred COMPOUNDS OF THE INVENTION are compounds of formula I
A is C1-12alkyl, C7-10phenylalkyl or a group of formula RCO-, whereby
i) R is hydrogen, C1-11alkyl, phenyl or C7-10phenylalkyl, or ii) RCO- is a) an L- or D-phenylalanine residue optionally ring-substituted by halogen, NO2, NH2, OH, C1-3alkyl and/or C1-3alkoxy; b) the residue of a natural or a non natural α-amino-acid other than defined under a) above, or of a corresponding D-amino acid, or c) a dipeptide residue in which the individual amino acid
residues are the same or different and are selected from those defined under a) and/or b) above, the α-amino group of amino acid residues a) or b) and the N-terminal amino group of dipeptide residues c) being optionally mono- or di-C1-12alkylated or substituted by C1-8alkanoyl or benzyl;
A' is hydrogen or C1-3alkyl,
Y1 and Y2 represent together a direct bond or
each of Y1 and Y2 is independently hydrogen or a radical of
Ra is methyl or ethyl
Rb is hydrogen, methyl or ethyl
m is a whole number from 1 to 4
n is a whole number from 1 to 5
Rc is (C1-6)alkyl
Rd represents the substituent attached to the α-carbon atom of a natural or non natural α-amino acid (including hydrogen) Re is (C1-5)alkyl
Ra' and Rb' are independently hydrogen, methyl or ethyl,
R8 and R9 are independently hydrogen, halogen, (C1-3)alkyl or
(C1-3)alkoxy,
p is 0 or 1,
q is 0 or 1, and
r is 0, 1 or 2,
B is -Phe- optionally ring-substituted by halogen, NO2, NH2, OH, C1-3alkyl and /or C1-3alkoxy (including pentafluoro- alanine), or naphthylalanine
C is (L)-Trp- or (D)-Trp- optionally α-N-methylated and optionally benzene-ring-substituted by halogen, NO2, NH2, OH, C1-3alkyl and/or C1-3alkoxy,
D is Lys, Lys in which the side chain contains O or S in
β-position, γF-Lys or δF-Lys, optionally α-N-methylated, or a 4-aminocyclohexylAla or 4-aminocyclohexylGly residue
E is Thr, Ser, Val, Phe, Tyr, Ile or an aminobutyric or aminoisobutyric acid residue
G is a group of formula
wherein
R7 is hydrogen or C1-3alkyl,
R10 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,
R11 is hydrogen, C1-3alkyl, phenyl or C7-10phenyl-alkyl,
R12 is hydrogen, C1-3alkyl or a group of formula -CH(R13)-X1, R13 is CH2OH, -(CH2)2-OH, -(CH2)3-OH, or -CH(CH3)OH or represents the substituent attached to the α-carbon atom of a natural or non natural α-amino acid (including hydrogen) and
R7 and R10 have the meanings given above,
R14 is hydrogen or C1-3alkyl and
R15 is hydrogen, C1-3alkyl, phenyl or C7-10phenylalkyl, and
R16 is hydrogen or hydroxy, with the proviso that
when R12 is -CH(R13)-X1 then R11 is hydrogen or methyl, wherein the residues B, D and E have the L-configuration, and the residues in the 2- and 7-position and any residues Y1 4) and Y2 4) each independently have the (L)- or (D)- configuration, in free form or in pharmaceutically acceptable salt or complex form.
Phenylalkyl as A or R is preferably phenethyl.
In the compounds of formula (I), the following significances are preferred either individually or in any combination or
sub-combination:
1.1. When R has the meaning a) this is preferably a') an L- or D-phenylalanine or -tyrosine residue. More preferably a') is an L- or D-phenylalanine residue.
1.2. When R has the meaning b) or c) the defined residue is preferably lipophilic. Preferred residues b) thus b') are α-amino acid residues having a hydrocarbon side chain, e.g. alkyl with 3, preferably 4, or more C atoms, e.g. up to 7 C-atoms, or a naphthyl-methyl or heteroaryl side chain, e.g. pyridyl-methyl or indol-3-yl-methyl, said residues having the L- or D-configuration. Preferred residues c) are dipeptide residues in which
the individual amino acid residues are the same or different and are selected from those defined under a') and b') above.
1.3. When RCO has the meanings a), b) or c), the α-amino group of amino acid residues a) and b) and the
N-terminal amino group of dipeptide residues c) is preferably non-alkylated or mono-C1-12 alkylated, especially -C1-8 alkylated, more especially -methylated. Most preferably the N-terminal is non-alkylated.
1.4. Most preferably R has the meaning a) especially the meaning a').
2. B is B', where B' is Phe or Tyr.
3. C is C, where C is (D)Trp.
4. D is D', where D' is Lys, MeLys, especially Lys.
5. E is E', where E' is Ser, Val or Thr, especially Thr.
6. G is G', where G' is a group of formula
(in which case R11=H or CH3). In the latter case the moiety -CH(R13)-X1 preferably has the L-configuration.
6.1. R11 is preferably hydrogen.
6.2. As the substituent attached to the α-carbon atom of a natural or non natural amino acid (i.e. of formula H2N-CH(R13)-COOH), R13 is preferably -CH2OH,
-CH(CH3)-OH, -(CH2)2-OH, -(CH2)3-OH, isobutyl, butyl, naphthyl-methyl or indol-3-yl-methyl. It is especially -CH2OH or -CH(CH3)OH.
6.3. X1 is preferably a group of formula
or -CH2-OR10, especially of formula -CH2-OR10 and R10 is preferably hydrogen or, as an ester residue, formyl, C2-12 alky1carbony1, C8-12 phenylalkylcarbonyl or benzoyl. Most preferably R10 is hydrogen.
Individual compounds suitable for use in accordance with the present invention are the following somatostatin analogues:
The COMPOUNDS OF THE INVENTION may exist e.g. in free form, salt form or in the form of complexes thereof. Acid addition salts may be formed with e.g. organic acids, polymeric acids and inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides and acetates. Complexes are e.g. formed from compounds of the invention on addition of inorganic substances, e.g.
inorganic salts or hydroxides such as Ca- and Zn-salts, and/or an addition of polymeric organic substances.
COMPOUNDS OF THE INVENTION have, on the basis of observed activity, e.g. inhibition of GH secretion in rats and/or inhibition of pancreatic and gastric secretion in rats, e.g. as described in EP-B-29579, been found to be useful e.g. in the treatment of acromegaly, complications of diabetes mellitus or gastro-intestinal disorders.
It has also been reported that injections of octreotide can alleviate chronic, life disrupting headache associated with acromegaly and prolactinoma (G. Williams et al, Brit. Med. J., 295, 247-248, 1987). This kind of chronic headache is related to the presence of pituitary tumors. Although other factors in addition to the space occupying effects of the tumor may be involved, it is accepted that this chronic headache has a pathogenesis distinct from that of migraine or cluster headache according to the International Classification of headache disorders, cranial neuralgias and facial pain, Cephalalgia 1988, 8 suppl. 7, 1-96. Even more the usual treatments proposed for headache and migraine are so far generally ineffective in the management of headache associated with acromegaly and
prolactinoma.
Migraine is a familial disorder characterized by periodic commonly unilateral, throbbing headaches which begin in
childhood, adolescence or adult life. Migraine episodes usually have one or more of the following characteristics; episodic nature lasting 4-72 hours, unilateral location, accompanying nausea, pulsating characteristic of pain, photophobia and phonophobia, autonomic disturbances and tenderness of the scalp on the side of the headache. One main aspect of the treatment consists in pharmacologically aborting acute attacks.
Unfortunately, current therapy is limited in some cases by inadequate efficacy and disagreable side effects. There thus exists a need for acute treatment of migraine attacks.
Cluster headache is a craniofacial pain syndrome which can be distinguished clinically from migraine. Attacks of headache occur in clusters during a period of weeks or months followed by often prolonged painfree periods. Between 1 and 4 attacks of 10-240 min duration may occur in a single day. There also exists a need for adequate treatment of cluster headache attacks.
In accordance with the present invention, it has now surprisingly been found that COMPOUNDS OF THE INVENTION, when administered nasally, have a fast onset of action in the treatment of acute attacks of migraine or cluster headache in subjects who do not suffer from pituitary tumors.
In accordance with the particular findings of the present invention, there is provided in a first aspect:
1. A method for treating acute attacks of migraine or cluster headache in a subject in need of such therapy comprising administering nasally to said subject a therapeutically effective amount of a COMPOUND OF THE INVENTION.
As alternative to the above, the present invention also provides:
2. A COMPOUND OF THE INVENTION for nasal use in the treatment of acute attacks of migraine or cluster headache.
3. A COMPOUND OF THE INVENTION for use in the manufacture of a nasal pharmaceutical composition for use in the treatment of acute attacks of migraine or cluster headache.
4. A nasal pharmaceutical composition for use in the treatment of acute attacks of migraine or cluster headache, comprising a COMPOUND OF THE INVENTION together with one or more diluents or carriers adapted for nasal administration.
The COMPOUNDS OF THE INVENTION are administered in the form of a composition adapted for nasal administration. They may be administered in the form of liquid or solid, e.g. in nasal spray, drop, gel or powder form, or nasal inserts.
Liquid nasal compositions may comprise a COMPOUND OF THE
INVENTION together with a liquid diluent or carrier suitable for application to the nasal mucosa, e.g. water or aqueous saline. Such compositions may contain further ingredients or excipients, e.g.
- a substance for adjusting the pH, preferably tp a mildly acid pH, e.g. of from about 4 to 5, preferably about 4.2, for example a mineral or organic acid, e.g. HCl,
- a substance for adjusting isotonicity, e.g. glucose, ribose, mannose, arabinose, xylose, glucosamine or NaCl,
- a stabilizing and/or preserving agent, e.g. thiomersal,
benzalkonium chloride, cetrimide, paraben etc.
Such a preserving agent may be present in an amount of from ca. 0.05 to 0.2 mg/ml.
Suitable nasal inserts include e.g. a device which is sized, shaped or adapted for placement and retention into the naris e.g. nasal plugs, tampons and the like, breathing being not significantly inhibited. The COMPOUND OF THE INVENTION may be carried on the insert, e.g. by adsorption onto the surface thereof or in the form of a coating, and/or in the insert, e.g. by absorption or by any other convenient means. The COMPOUND OF THE INVENTION may be carried in combination with one or more nasally acceptable diluents or carriers. The material from which the insert is made may be for example a porous material, e.g. a polymer capable of forming a porous matrix, e.g. gelatin, acrylate polymers, hydroxypropyl cellulose, hydroxypropylmethyl cellulose (HPMC), or a fibrous material such as cotton wool or sponge material. Such nasal inserts are e.g. disclosed in UK Patent Application 2,176,105 A, the contents of which relating to the nasal inserts being incorporated herein by reference.
Preferably the COMPOUNDS OF THE INVENTION may be administered in the form of a powder.
Examples of nasal powdered compositions suitable for the treatment according to the invention may be based on a carrier such as lactose or water-absorbing, water-insoluble,
water-swellable or water-soluble polymers. Examples of such polymers are e.g. polyacrylates such as sodium polyacrylate, potassium polyacrylate and ammonium polyacrylates; lower alkyl ethers of cellulose such as methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose; polyvinyl pyrrolidone, amylose and preferably polyethyleneglycol e.g. of MW from 1000 to 8000, hydroxypropylmethyl cellulose, microcrystalline cellulose, cellulose,
α-cellulose, and cross-linked sodium carboxymethyl cellulose, water-absorbing and water-insoluble starches such as hydroxypropyl starch, carboxymethyl starch, water-absorbing and water-insoluble proteins such as gelatin, casein; water-absorbing and water-insoluble gums such as gum arabic, tragacanth gum and glucomannan; and cross-linked vinyl polymers such as cross-linked polyvinyl pyrrolidone, cross-linked carboxyvinyl polymer or its salt, cross-linked polyvinyl alcohol and polyhydroxyethylmethylacrylate. Of these mentioned above, water-absorbing and water-insoluble celluloses and cross-linked vinyl polymers are desirable, and water-absorbing and water-insoluble celluloses are more desirable and microcrystalline cellulose is especially desirable.
Preferably the mean polymerisation number of the preferred polymers, microcrystalline cellulose, is from about 200 to 2000, preferably 200 to 300. Preferred mean molecular weights are from about 20.000 to about 100.000 e.g. 30.000 to 50.000.
These powders may be prepared by mixing a COMPOUND OF THE
INVENTION with the particles, e.g. a polymer base in conventional manner.
If desired the particles may be coated. The COMPOUND may be in solution, e.g. an aqueous or alcoholic solution when being mixed with the particles and the solvent evaporated, e-g. under freeze-drying or spray drying. Such drying may be effected under conventional conditions. Alternatively the mixture may be compacted or granulated and then be pulverized and/or sieved. If desired the powder may be produced in the form of an insert e.g. as described above and then pulverized.
Preferably the powder has a particle size of from 10 to
250 microns.
The powdery pharmaceutical composition can be directly used as a powder for a unit dosage form. If desired the powder can be filled in capsules such as hard gelatine capsules. The contents of the capsule may be administered using e.g. an insufflator. The nasal powder may contain other excipients. Some excipients have been described above. For example sugars, such as lactose, stabilizing agents, isotonic agents may be present in the powder-form.
If desired the nasal powder to be used according to the invention may also contain an absorption promoter, in particular a non-ionic promoter, e.g. a non-ionic surfactant, suitable for application to the nasal mucosae.
Compositions adapted for nasal administration are disclosed e.g. in GB-A-2, 193,891, the contents of which being incorporated herein by reference. A particularly preferred nasal composition for use in the method of the invention is a powdery composition comprising a water-absorbing, water-insoluble diluent or carrier, e.g. microcrystalline cellulose.
An example of such a powdery composition is a composition comprising from 2.2 to 1.6 mg of a COMPOUND OF THE INVENTION, particularly octreotide, per 20 mg powder.
Utility of the COMPOUNDS OF THE INVENTION in the nasal treatment of acute attacks of migraine or cluster headache as hereinabove specified, may be demonstrated clinically, for example in accordance with the method hereinafter described.
84 patients either male or female, age 18 to 60, having at least a one year history of migraine without aura are submitted to a double-blind, cross-over, placebo-controlled clinical study.
The diagnosis of migraine without aura fulfills the criteria of the International Headache Society's Headache Classification Committee (Appendix G).
Patients are included who have a mean monthly frequency of 2 to 6 attacks of migraine without aura/month during 3 months prior to entering the study period. Preferably the clinical trial excludes:
- patients having a different type of cephalalgia, e.g.
tension-type headaches
- patients having less than 2 migraine attacks per month or more than 6 migraine attacks per month
- females who are pregnant, breast-feeding or not using medically accepted contraceptive measures
- patients suffering from one of the following disorders:
* diabetes
* obstruent intestinal tumor
* hepatic and renal insufficiency
* known cholelithiasis
* rhinopharyngeal pathology
* asthma
* serious psychiatric disorders
Each patient receives three medication boxes containing each one capsule and an insufflator. Two capsules contain the compound to be tested, in powder form and at various concentrations; the third capsule is a placebo capsule. All three capsules are identical in their aspect.
The migraine attack is treated within 3 hours following its onset. Migraine attacks are rated
1 = slight migraine attack
2 = moderate migraine attack
3 = severe migraine attack
Only migraine attacks rated a 2 or 3 are treated. The patient administers to himself a total of 6 puffs, which permits to empty the capsule. Administration is made alternatively in each nostril (3/nostril). The patient uses the box corresponding to the particular attack (box labelled no. 1 for the first attack, no. 2 for the second migraine attack and no. 3 for the third attack). Two hours after administration, the patient is allowed to take another migraine medication, except for a nasal medication, if its symptoms have not improved.
At the study inclusion, the physician records the migraine history of the patient, the results of neurologic and
craniocervical examination and blood pressure.
The patient rates the severity of the migraine attack
1) by choosing a score between 0 and 3
0: no headache
1: mild headache allowing a normal activity
2: moderate headache impairing the normal activity but without interruption or need to lay down 3: severe headache which necessitates to interrupt the normal activity or to lay down
2) by placing a mark on a visual analog scale of 100 mm
This rating is done immediately before the nasal administrations, and then 30, 60, 120 minutes, 8 and 24 hours after the nasal administration. The patient records also: the total duration of the migraine attack; whether he needs a complementary medication; the existence of nausea and/or vomiting before and 2 hours after
the treatment; rebound of migraine within the 24 hours after the treatment.
In this study, patients treated nasally with a COMPOUND OF THE INVENTION at a dosage of 0.5 to 2 mg exhibit a significant to complete relief within 2 hours after the nasal administration. With Octreotide, for example, there is obtained an onset of action within 10 to 20 minutes after nasal administration at the above indicated dosage.
In a similar study comprising 48 patients with cluster headache, similarly good results are obtained when the COMPOUNDS OF THE INVENTION are administered nasally at a dosage of 0.5 to 2 mg.
Daily dosages required in practicing the method of the present invention will, of course, vary depending on a variety of factors, for example the particular COMPOUND OF INVENTION chosen, the particular condition to be treated and the effect desired. In general however satisfactory results are indicated to be obtained at a dosage for nasal administration from about 3.5 μg/kg to about 300 μk/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range of from ca. 0.25 to 2 mg nasally. Suitable unit dosage forms for nasal administration thus comprise from ca. 0.25 to 2 mg active compound together with one or more pharmaceutically acceptable diluents or carriers therefor.
The following is illustrative of the preparation of a composition for nasal administration in accordance with the invention.
EXAMPLE 1: Nasal liquid spray
Composition
INGREDIENT QUANTITY/ml end composition 1. Octreotide acetate 7.796 mg*
+ 5 % excess 0.390 mg
8.186 mg
2. Glucose 50.0 mg
3. 0.1 N HCl to pH 4.20
4. Benzalkonium chloride 0.11 mg
5. H2O (injection grade) to an end volume of 1.0 ml * = 6.315 mg free peptide
EXAMPLE 2: Nasal liquid spray
Example 1 is repeated but with addition of 3.0 mg/ml end composition powdered SOLULAN C24 (Polyoxyethylene-(24)-cholesteryl ether) together with components 1, 2 and 4 in the first production step.
EXAMPLE 3: Nasal lyophilisate insert
A lyophilisate insert (plug) is made comprising the following: mg
Octreotide acetate 0.3151)
Lactose 1.0
HPMC (Methocel E5) 1.5
PEG (MW 4000) 1.5
1) Equivalent to 0. 25 mg free peptide
EXAMPLE 4: Nasal powder
A nasal powder is prepared containing:
mg octreotide ac 1.32
+ 5% excess 0.07
Microcrystalline cellulose (Avicel PH 101- 18.61
particle size 38-68 microns)
Total 20
This powder is prepared in a charge for about 300 unit doses by mixing octreotide and about one quarter of the cellulose. The
mixture is sieved. The remainder of the cellulose is then added and the mass is mixed thoroughly.
The final powder has a particle diameter from about 20 to about 250 μ. This powder is filled into capsules. Local and systemic tolerability is good for this nasal powder.
Claims
1. A method for treating acute attacks of migraine or cluster headache in a subject in need of such therapy comprising, administering nasally to said subject a therapeutically effective amount of a somatostatin peptide analogue or derivative, in free form or in pharmaceutically acceptable salt or complex form.
2. A nasal pharmaceutical composition for use in the treatment of acute attacks of migraine or cluster headache, comprising a somatostatin peptide analogue or derivative, in free form or in pharmaceutically acceptable salt or complex form, together with one or more diluents or carriers adapted for nasal administration.
3. A somatostatin peptide analogue or derivative, in free form or in pharmaceutically acceptable salt or complex form, for use in the manufacture of a nasal pharmaceutical composition for use in the treatment of acute attacks of migraine or cluster headache.
4. A method, composition or use according to claim 1, 2 or 3, wherein the somatostatin peptide analogue or derivative is a compound of formula I
A is C1-12alkyl, C7-10phenylalkyl or a group of formula RCO-, whereby
i) R is hydrogen, C1-11alkyl, phenyl or C7-10phenylalkyl, or ii) RCO- is a) an L- or D-phenylalanine residue optionally ring-substituted by halogen, NO2, NH2, OH, C1-3alkyl and/or C1-3alkoxy; b) the residue of a natural or a non natural α-amino-acid other than defined under a) above, or of a corresponding D-amino acid, or c) a dipeptide residue in which the individual amino acid
residues are the same or different and are selected from those defined under a) and/or b) above, the α-amino group of amino acid residues a) or b) and the N-terminal amino group of dipeptide residues c) being optionally mono- or di-C1-12alkylated or substituted by C1-8alkanoyl or. benzyl;
A' is hydrogen or C1-3alkyl,
Y1 and Y2 represent together a direct bond or
each of Y1 and Y2 is independently hydrogen or a radical of
formulae (1) to (5)
Ra is methyl or ethyl
Rb is hydrogen, methyl or ethyl
m is a whole number from 1 to 4
n is a whole number from 1 to 5
Rc is (C1-6)alkyl
Rd represents the substituent attached to the α-carbon atom of a natural or non natural α-amino acid (including hydrogen)
Re is (C1-5)alkyl
Ra' and Rb' are independently hydrogen, methyl or ethyl,
R8 and R9 are independently hydrogen, halogen, (C1-3)alkyl or
(C1-3)alkoxy,
P is 0 or 1,
q is 0 or 1, and
r is 0, 1 or 2,
B is -Phe- optionally ring-substituted by halogen, NO2, NH2, OH, C1-3alkyl and /or C1-3alkoxy (including pentafluoro- alanine), or naphthylalanine
C is (L)-Trp- or (D)-Trp- optionally α-N-methylated and
optionally benzene-ring-substituted by halogen, NO2, NH2, OH, C1-3alkyl and/or C1-3alkoxy,
D is Lys, Lys in which the side chain contains 0 or S in
β-position, γF-Lys or δF-Lys, optionally α-N-methylated, or a 4-aminocyclohexylAla or 4-aminocyclohexylGly residue E is Thr, Ser, Val, Phe, Tyr, Ile or an aminobutyric or amino- isobutyric acid residue
G is a group of formula
wherein
R7 is hydrogen or C1-3alkyl,
R10 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,
R11 is hydrogen, C1-3alkyl, phenyl or C7-10phenyl-alkyl,
R12 is hydrogen, C1-3alkyl or a group of formula -CH(R13)-X1, R13 is CH2OH, -(CH2)2-OH, -(CH2)3-OH, or -CH(CH3)OH or represents the substituent attached to the α-carbon atom of a natural or non natural α-amino acid (including hydrogen) and
wherein
R7 and R10 have the meanings given above,
R14 is hydrogen or C1-3alkyl and
R15 is hydrogen, C1-3alkyl, phenyl or C7-10phenylalkyl, and
R16 is hydrogen or hydroxy, with the proviso that
when R12 is -CH(R13)-X1 then R11 is hydrogen or methyl, wherein the residues B, D and E have the L-configuration, and the residues in the 2- and 7-position and any residues Y1 4) and Y2 4) each independently have the (L)- or (D)- configuration, in free form or in pharmaceutically acceptable salt or complex form.
5. A method, composition or use according to claim 1, 2 or 3 wherein the somatostatin peptide analogue or derivative is selected from
6. A method, composition or use according to claim 1, 2 or 3 wherein the somatostatin peptide analogue or derivative is in the form of a nasal powder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929203769A GB9203769D0 (en) | 1992-02-21 | 1992-02-21 | Improvements in or relating to organic compounds |
GB9203769.6 | 1992-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993017037A1 true WO1993017037A1 (en) | 1993-09-02 |
Family
ID=10710831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/000366 WO1993017037A1 (en) | 1992-02-21 | 1993-02-16 | Treatment of acute migraine or cluster headache attacks |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB9203769D0 (en) |
WO (1) | WO1993017037A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2322077A (en) * | 1996-10-07 | 1998-08-19 | Fuji Yakuhin Kogyo Kk | Pharmaceutical preparation for intranasal administration |
WO2007025286A2 (en) * | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
US9133262B2 (en) * | 1996-12-04 | 2015-09-15 | Ipsen Pharma S.A.S. | Somatostatin antagonists |
US9629894B2 (en) | 2015-01-07 | 2017-04-25 | Trigemina, Inc. | Magnesium-containing oxytocin formulations and methods of use |
US10238709B2 (en) | 2015-02-03 | 2019-03-26 | Chiasma, Inc. | Method of treating diseases |
GB2567285A (en) * | 2017-08-07 | 2019-04-10 | Suprapharm Cc | Preparation for nasal-nasopharyngeal treatment |
US10682387B2 (en) | 2014-12-10 | 2020-06-16 | Chiasma, Inc. | Oral octreotide administered in combination with other therapeutic agents |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
WO2022159593A1 (en) * | 2021-01-21 | 2022-07-28 | Nbo Pharma Llc | Intranasal formulations and delivery of somatostatin mimetics and uses thereof |
US11400159B2 (en) | 2008-09-17 | 2022-08-02 | Amryt Endo, Inc. | Pharmaceutical compositions and related methods of delivery |
WO2022182779A1 (en) * | 2021-02-24 | 2022-09-01 | Nbo Pharma Llc | Methods and therapeutic combinations for treating idiopathic intracranial hypertension and cluster headaches |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3416374A1 (en) * | 1983-05-04 | 1984-11-15 | Istituto Farmacologico Serono S.P.A., Rom | USE OF SOMATOSTATIN FOR THE TREATMENT OF IDIOPATHIC HEADACHES |
EP0255224A2 (en) * | 1986-06-30 | 1988-02-03 | Merck & Co. Inc. | Cyclic and bridged cyclic somatostatin analogs useful as analgesic agents |
GB2193891A (en) * | 1986-08-18 | 1988-02-24 | Sandoz Ltd | Nasal pharmaceutical compositions containing octreotide |
EP0374089A2 (en) * | 1988-11-11 | 1990-06-20 | Sandoz Ag | Use of somatostatin derivatives as lung protecting agents |
EP0462071A1 (en) * | 1990-06-15 | 1991-12-18 | Sandoz Ltd. | Pharmaceutical resorption-improved somatostatin compositions, their preparation and use |
-
1992
- 1992-02-21 GB GB929203769A patent/GB9203769D0/en active Pending
-
1993
- 1993-02-16 WO PCT/EP1993/000366 patent/WO1993017037A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3416374A1 (en) * | 1983-05-04 | 1984-11-15 | Istituto Farmacologico Serono S.P.A., Rom | USE OF SOMATOSTATIN FOR THE TREATMENT OF IDIOPATHIC HEADACHES |
EP0255224A2 (en) * | 1986-06-30 | 1988-02-03 | Merck & Co. Inc. | Cyclic and bridged cyclic somatostatin analogs useful as analgesic agents |
GB2193891A (en) * | 1986-08-18 | 1988-02-24 | Sandoz Ltd | Nasal pharmaceutical compositions containing octreotide |
EP0374089A2 (en) * | 1988-11-11 | 1990-06-20 | Sandoz Ag | Use of somatostatin derivatives as lung protecting agents |
EP0462071A1 (en) * | 1990-06-15 | 1991-12-18 | Sandoz Ltd. | Pharmaceutical resorption-improved somatostatin compositions, their preparation and use |
Non-Patent Citations (1)
Title |
---|
BRITISH MEDICAL JOURNAL vol. 295, 25 July 1987, pages 247 - 248 G. WILLIAMS ET AL. 'Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours' cited in the application * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2322077A (en) * | 1996-10-07 | 1998-08-19 | Fuji Yakuhin Kogyo Kk | Pharmaceutical preparation for intranasal administration |
US9133262B2 (en) * | 1996-12-04 | 2015-09-15 | Ipsen Pharma S.A.S. | Somatostatin antagonists |
JP2009506076A (en) * | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | Therapeutic procedures for drug delivery for trigeminal neuralgia |
WO2007025286A3 (en) * | 2005-08-26 | 2007-05-10 | Univ Leland Stanford Junior | Therapy procedure for drug delivery for trigeminal pain |
WO2007025286A2 (en) * | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
US8501691B2 (en) | 2005-08-26 | 2013-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
JP2009506071A (en) * | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | Method for the treatment of headache by administration of oxytocin |
JP2013060464A (en) * | 2005-08-26 | 2013-04-04 | Board Of Trustees Of The Leland Stanford Jr Univ | Therapy procedure for drug delivery for trigeminal pain |
US8258096B2 (en) | 2005-08-26 | 2012-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
US8198240B2 (en) | 2005-08-26 | 2012-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US8202838B2 (en) | 2005-08-26 | 2012-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US8252745B2 (en) | 2005-08-26 | 2012-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US20110319329A1 (en) * | 2007-01-02 | 2011-12-29 | Novartis Ag | Use of somatostatin analogs in cluster headache |
AU2008203708B2 (en) * | 2007-01-02 | 2011-12-01 | Novartis Ag | Use of somatostatin analogs in cluster headache |
EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
WO2008081013A1 (en) * | 2007-01-02 | 2008-07-10 | Novartis Ag | Use of somatostatin analogs in cluster headache |
US11400159B2 (en) | 2008-09-17 | 2022-08-02 | Amryt Endo, Inc. | Pharmaceutical compositions and related methods of delivery |
US11986529B2 (en) | 2008-09-17 | 2024-05-21 | Amryt Endo, Inc. | Pharmaceutical compositions and related methods of delivery |
US11969471B2 (en) | 2008-09-17 | 2024-04-30 | Amryt Endo, Inc. | Pharmaceutical compositions and related methods of delivery |
US10682387B2 (en) | 2014-12-10 | 2020-06-16 | Chiasma, Inc. | Oral octreotide administered in combination with other therapeutic agents |
US9629894B2 (en) | 2015-01-07 | 2017-04-25 | Trigemina, Inc. | Magnesium-containing oxytocin formulations and methods of use |
US11389473B2 (en) | 2015-01-07 | 2022-07-19 | Tonix Pharmaceuticals Holding Corp. | Magnesium-containing oxytocin formulations and methods of use |
US11052126B2 (en) | 2015-02-03 | 2021-07-06 | Chiasma, Inc. | Method of treating diseases |
US11338011B2 (en) | 2015-02-03 | 2022-05-24 | Amryt Endo, Inc. | Method of treating diseases |
US10695397B2 (en) | 2015-02-03 | 2020-06-30 | Chiasma, Inc. | Method of treating diseases |
US11510963B1 (en) | 2015-02-03 | 2022-11-29 | Amryt Endo, Inc. | Method of treating diseases |
US11857595B2 (en) | 2015-02-03 | 2024-01-02 | Amryt Endo, Inc. | Method of treating diseases |
US10238709B2 (en) | 2015-02-03 | 2019-03-26 | Chiasma, Inc. | Method of treating diseases |
GB2567285A (en) * | 2017-08-07 | 2019-04-10 | Suprapharm Cc | Preparation for nasal-nasopharyngeal treatment |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
US11890316B2 (en) | 2020-12-28 | 2024-02-06 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
WO2022159593A1 (en) * | 2021-01-21 | 2022-07-28 | Nbo Pharma Llc | Intranasal formulations and delivery of somatostatin mimetics and uses thereof |
WO2022182779A1 (en) * | 2021-02-24 | 2022-09-01 | Nbo Pharma Llc | Methods and therapeutic combinations for treating idiopathic intracranial hypertension and cluster headaches |
Also Published As
Publication number | Publication date |
---|---|
GB9203769D0 (en) | 1992-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7381702B2 (en) | Methods of treating diabetes mellitus | |
US5877277A (en) | Octapeptide bombesin analogs | |
WO1993017037A1 (en) | Treatment of acute migraine or cluster headache attacks | |
JP2578477B2 (en) | Improvements on softstatins | |
JPH05508616A (en) | therapeutic aerosol | |
CA2416643A1 (en) | Ghrelin antagonists | |
AU2002244020A1 (en) | Methods of treating diabetes mellitus | |
ZA200406332B (en) | ACC inhibitors. | |
KR930003332B1 (en) | Process for preparing composition contained antidiuretically effective amount of 1-deamino-8-d-arginine | |
WO1990009167A1 (en) | Composition and method for administration of pharmaceutically active substances | |
US20050080007A1 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
GB2193891A (en) | Nasal pharmaceutical compositions containing octreotide | |
CA2416475A1 (en) | Medicinal uses of mu-opioid receptor agonists | |
Marbach et al. | Clinical applications of somatostatin analogs | |
AU631547B2 (en) | Treatment of arthritis | |
JP2764930B2 (en) | Pharmaceutical composition with enhanced peptide or protein absorption | |
IE862433L (en) | Somatostatin analogs | |
Reissmann et al. | Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone | |
Dallabonzana et al. | Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly | |
GB2239178A (en) | Somatostatin analogues for the treatment of breast cancer | |
WO2002009739A1 (en) | Treatment of ocular disorders with somatostatin analogues | |
KR100195894B1 (en) | Pharmaceutical compositions containing somatostatin analogues | |
CA2263042A1 (en) | Treatment of edema | |
JP2764041B6 (en) | Improvements on somatostatins | |
JPS6072824A (en) | Medicine for metabolism dysfunction treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WA | Withdrawal of international application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |